OncoMatch

OncoMatch/Clinical Trials/NCT04778839

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Is NCT04778839 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Paclitaxel and Paclitaxel Micelles for for advanced solid tumors.

Phase 1RecruitingFirst Affiliated Hospital of Zhejiang UniversityNCT04778839Data as of Jun 2026

Treatment: Paclitaxel · Paclitaxel Micelles forA Phase I Study of Dose Escalation and Dose Expansion To Evaluate the Safety、Tolerability、Pharmacokinetics and Preliminary Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

PaclitaxelPaclitaxel Micelles for

Cancer type

Tumor Agnostic

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 70

Prior therapy

Cannot have received: paclitaxel

Exception: unless not resistant

Patients who had been treated with paclitaxel and were determined by the researchers to be resistant

Lab requirements

Blood counts

Hb ≥ 90 g/L, ANC ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L; no blood transfusion, blood products, or hematopoietic growth factors within 14 days prior to screening

Kidney function

creatinine ≤ 1.5×ULN and CL ≥ 60 mL/min

Liver function

ALT or AST ≤ 2.5×ULN (for patients with hepatic metastases, ALT or AST ≤ 5 × ULN); TBIL ≤ 1.5×ULN

Cardiac function

LVEF ≥ 50%

No severe hematopoietic abnormalities(no blood transfusion, no blood products, no granulocyte colony-stimulating factor, platelet stimulating factor, or other hematopoietic growth factors were corrected within 14 days prior to the screening phase laboratory examination):Hb≥90g/L , ANC≥1.5×109/L , PLT≥100×109/L. No serious organic disease of heart, liver or kidney:LVEF≥50% ; ALT(Alanine aminotransferase) or AST(Aspartate transaminase)≤2.5×upper limit of normal(ULN)(for patients with hepatic metastases, ALT or AST≤5 × ULN); TBIL(Total bilirubin)≤1.5×ULN; creatinine≤1.5×ULN and CL≥ 60 mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04778839 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior paclitaxel disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 70 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify